(Q28286911)

1

0 references

Hitoshi Yoshiji

2

0 references

Yasuhide Ikenaka

3

0 references

Ryuichi Noguchi

4

0 references

Yosuke Aihara

5

0 references

Akitoshi Douhara

6

0 references

Kei Moriya

7

0 references

Hideto Kawaratani

8

0 references

Yusaku Shirai

9

0 references

Junichi Yoshii

10

0 references

Koji Yanase

11

0 references

Mitsuteru Kitade

12

0 references

Tadashi Namisaki

13

0 references

Hiroshi Fukui

Journal of Gastroenterology

14

0 references

language of work or name

English

0 references

publication date

March 2014

0 references

published in

0 references

volume

49

0 references

issue

3

0 references

page(s)

481-91

0 references

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0783-4

Mechanisms of hepatic fibrogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0783-4

Liver fibrosis -- from bench to bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0783-4

Therapeutic targets in liver fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0783-4

Angiotensin-II type 1 receptor interaction is a major regulator for liver fibrosis development in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0783-4

Imatinib mesylate (STI-571) attenuates liver fibrosis development in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0783-4

Imatinib mesylate improves liver regeneration and attenuates liver fibrogenesis in CCL4-treated mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0783-4

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0783-4

Dipeptidyl peptidase-4 inhibitors: clinical data and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0783-4

The incretin system and its role in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0783-4

Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0783-4

Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0783-4

Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0783-4

Structure and function in dipeptidyl peptidase IV and related proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0783-4

Evidence for a role of dipeptidyl peptidase IV in fibronectin-mediated interactions of hepatocytes with extracellular matrix.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0783-4

The role of fetal and adult hepatocyte extracellular matrix in the regulation of tissue-specific gene expression in fetal and adult hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0783-4

Dipeptidyl peptidase activity of CD26 in serum and urine as a marker of cholestasis: experimental and clinical evidence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0783-4

Association of increased hepatitis C virus (HCV)-specific IgG and soluble CD26 dipeptidyl peptidase IV enzyme activity with hepatotoxicity after highly active antiretroviral therapy in human immunodeficiency virus-HCV-coinfected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0783-4

Intrahepatic expression of the hepatic stellate cell marker fibroblast activation protein correlates with the degree of fibrosis in hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0783-4

Fibroblast activation protein increases apoptosis, cell adhesion, and migration by the LX-2 human stellate cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0783-4

Dipeptidyl peptidase IV and related enzymes in cell biology and liver disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0783-4

Expression and spatial heterogeneity of dipeptidyl peptidases in endothelial cells of conduct vessels and capillaries.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0783-4

The role of CD26/dipeptidyl peptidase IV in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0783-4

Elevated serum dipeptidyl peptidase IV (CD26, EC 3.4.14.5) activity in experimental liver cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0783-4

Inhibitors of dipeptidyl peptidase IV-like activity mediate antifibrotic effects in normal and keloid-derived skin fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0783-4

DPP-4 (CD26) inhibitor alogliptin inhibits TLR4-mediated ERK activation and ERK-dependent MMP-1 expression by U937 histiocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0783-4

Emerging insights into Transforming growth factor beta Smad signal in hepatic fibrogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0783-4

Smad-dependent and Smad-independent pathways in TGF-beta family signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0783-4

SMAD and p38 MAPK signaling pathways independently regulate alpha1(I) collagen gene expression in unstimulated and transforming growth factor-beta-stimulated hepatic stellate cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0783-4

NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0783-4

A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0783-4

Glucagon-like peptide-1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0783-4

Beneficial endocrine but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes: interactions with metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0783-4

The combination of colesevelam with sitagliptin enhances glycemic control in diabetic ZDF rat model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0783-4

Contribution of immune response to the hepatic fibrosis induced by porcine serum

21 January 2018

1 reference

12 December 2020

AT1 receptor antagonist Candesartan in selected cirrhotic patients: Effect on portal pressure and liver fibrosis markers

1 reference

12 December 2020

Elevated serum dipeptidyl peptidase IV (CD26, EC 3.4.14.5) activity in patients with primary biliary cirrhosis

1 reference

12 December 2020

Rosiglitazone versus rosiglitazone and metformin versus rosiglitazone and losartan in the treatment of nonalcoholic steatohepatitis in humans: a 12-month randomized, prospective, open- label trial

1 reference

12 December 2020

Pharmacological inhibition of the vitronectin receptor abrogates PDGF-BB-induced hepatic stellate cell migration and activation in vitro

1 reference

12 December 2020

The role of metformin in the management of NAFLD

1 reference

12 December 2020

Different enzyme activities in coronary capillary endothelial cells.

1 reference

12 December 2020

Sitagliptin prevents the development of metabolic and hormonal disturbances, increased β-cell apoptosis and liver steatosis induced by a fructose-rich diet in normal rats

1 reference

12 December 2020

Aberrant dipeptidyl peptidase IV (DPP IV/CD26) expression in human hepatocellular carcinoma

1 reference

12 December 2020

Dual role of dipeptidyl peptidase IV (DPP IV) in angiogenesis and vascular remodeling

1 reference

12 December 2020

Fibroblast activation protein: A cell surface dipeptidyl peptidase and gelatinase expressed by stellate cells at the tissue remodelling interface in human cirrhosis

1 reference

12 December 2020

The effects of the selective mineralocorticoid receptor antagonist eplerenone on hepatic fibrosis induced by bile duct ligation in rat.

1 reference

12 December 2020

Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients

1 reference

12 December 2020

1 reference

12 December 2020

Isolation and culture of hepatic stellate cells

1 reference

12 December 2020

Selective aldosterone blocker ameliorates the progression of non-alcoholic steatohepatitis in rats

1 reference

12 December 2020

Serum dipeptidyl peptidase IV (DPP IV, CD26) activity in chronic hepatitis C

1 reference

12 December 2020